Literature DB >> 31312839

Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.

Jun Sung Lee1, Kazuaki Kanai2, Mari Suzuki3,4, Woojin S Kim5, Han Soo Yoo6, YuHong Fu5, Dong-Kyu Kim1, Byung Chul Jung1, Minsun Choi1, Kyu Won Oh1, Yuanzhe Li2, Mitsuyoshi Nakatani2, Tomoko Nakazato2, Satoko Sekimoto2, Manabu Funayama2, Hiroyo Yoshino2, Shin-Ichiro Kubo2, Kenya Nishioka2, Ryusuke Sakai4,7, Morio Ueyama4, Hideki Mochizuki7, He-Jin Lee8, Sergio Pablo Sardi9, Glenda M Halliday5, Yoshitaka Nagai4,7, Phil Hyu Lee6, Nobutaka Hattori2, Seung-Jae Lee1.   

Abstract

Mutations in lysosomal genes increase the risk of neurodegenerative diseases, as is the case for Parkinson's disease. Here, we found that pathogenic and protective mutations in arylsulfatase A (ARSA), a gene responsible for metachromatic leukodystrophy, a lysosomal storage disorder, are linked to Parkinson's disease. Plasma ARSA protein levels were changed in Parkinson's disease patients. ARSA deficiency caused increases in α-synuclein aggregation and secretion, and increases in α-synuclein propagation in cells and nematodes. Despite being a lysosomal protein, ARSA directly interacts with α-synuclein in the cytosol. The interaction was more extensive with protective ARSA variant and less with pathogenic ARSA variant than wild-type. ARSA inhibited the in vitro fibrillation of α-synuclein in a dose-dependent manner. Ectopic expression of ARSA reversed the α-synuclein phenotypes in both cell and fly models of synucleinopathy, the effects correlating with the extent of the physical interaction between these molecules. Collectively, these results suggest that ARSA is a genetic modifier of Parkinson's disease pathogenesis, acting as a molecular chaperone for α-synuclein.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; arylsulfatase A; molecular chaperone; protein aggregation and propagation; α-synuclein

Year:  2019        PMID: 31312839     DOI: 10.1093/brain/awz205

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

Review 1.  Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia.

Authors:  Jun Yup Lee; Oana C Marian; Anthony S Don
Journal:  Neuromolecular Med       Date:  2021-02-07       Impact factor: 3.843

Review 2.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.

Authors:  Sara Bandres-Ciga; Monica Diez-Fairen; Jonggeol Jeff Kim; Andrew B Singleton
Journal:  Neurobiol Dis       Date:  2020-01-25       Impact factor: 5.996

Review 3.  GBA1 and The Immune System: A Potential Role in Parkinson's Disease?

Authors:  Zaid A M Al-Azzawi; Saman Arfaie; Ziv Gan-Or
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

5.  Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.

Authors:  Estera Rintz; Lidia Gaffke; Magdalena Podlacha; Joanna Brokowska; Zuzanna Cyske; Grzegorz Węgrzyn; Karolina Pierzynowska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 6.  Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease.

Authors:  Silvia Paciotti; Elisabetta Albi; Lucilla Parnetti; Tommaso Beccari
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

7.  ARSA variants in α-synucleinopathies.

Authors:  Mary B Makarious; Monica Diez-Fairen; Lynne Krohn; Cornelis Blauwendraat; Sara Bandres-Ciga; Jinhui Ding; Lasse Pihlstrøm; Henry Houlden; Sonja W Scholz; Ziv Gan-Or
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

8.  Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease.

Authors:  Han Soo Yoo; Jun Sung Lee; Seok Jong Chung; Byoung Seok Ye; Young H Sohn; Seung-Jae Lee; Phil Hyu Lee
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

Review 9.  Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery.

Authors:  Laura Rigon; Concetta De Filippis; Barbara Napoli; Rosella Tomanin; Genny Orso
Journal:  Biomedicines       Date:  2021-03-07

10.  Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control.

Authors:  Magdalene K Montgomery; Jacqueline Bayliss; Shuai Nie; William De Nardo; Stacey N Keenan; Paula M Miotto; Hamzeh Karimkhanloo; Cheng Huang; Ralf B Schittenhelm; Anthony S Don; Andrew Ryan; Nicholas A Williamson; Geraldine J Ooi; Wendy A Brown; Paul R Burton; Benjamin L Parker; Matthew J Watt
Journal:  Nat Commun       Date:  2022-03-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.